Advertisement
Screener

Exelixis Inc (EXEL) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

3.5 / 5 stars · 77/111 Roast Me

Exelixis Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.

  • Exelixis Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-01-03 was 231.80K shares, a 39.50% decline year-over-year.
  • Exelixis Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-09-27 was 894.77K shares, a 4.99% decline year-over-year.
  • Exelixis Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-06-28 was 733.66K shares, a 14.04% decline year-over-year.
  • Exelixis Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-03-29 was 1.41M shares, a 390.56% increase year-over-year.
  • Exelixis Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2026 was 2.11M shares, a 30.91% decline from fiscal 2025.
  • Exelixis Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 3.05M shares, a 30.38% increase from fiscal 2023.
  • Exelixis Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 2.34M shares, a 14.69% decline from fiscal 2022.
  • Exelixis Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 2.74M shares, a 38.85% decline from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month
2026-01-022.11M shares
10-K · filed 2026-02-10
2025-01-033.05M shares
10-K · filed 2025-02-11
2023-12-292.34M shares
10-K · filed 2024-02-06
2022-12-302.74M shares
10-K · filed 2023-02-07
2021-12-314.49M shares
10-K · filed 2022-02-18
2021-01-015.63M shares
10-K · filed 2021-02-11
2020-01-03231.80K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
3.27M shares
10-K · filed 2020-02-25
2019-09-27894.77K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30
3.43M shares
derived: sum of 4 quarters · filed 2019-10-30
2019-06-28733.66K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31
3.47M shares
derived: sum of 4 quarters · filed 2019-07-31
2019-03-291.41M shares
10-Q · filed 2019-05-01
3.59M shares
derived: sum of 4 quarters · filed 2019-05-01
2018-12-28383.12K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22
2.47M shares
10-K · filed 2019-02-22
2018-09-28941.82K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
2.27M shares
derived: sum of 4 quarters · filed 2018-11-01
2018-06-29853.44K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01
2.37M shares
derived: sum of 4 quarters · filed 2018-08-01
2018-03-30288.20K shares
10-Q · filed 2018-05-02
2.46M shares
derived: sum of 4 quarters · filed 2018-05-02
2017-12-29186.36K shares
derived: 10-K 12 month − 3 quarters · filed 2018-02-26
4.47M shares
10-K · filed 2018-02-26
2017-09-301.04M shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
7.16M shares
derived: sum of 4 quarters · filed 2017-11-01
2017-06-30944.67K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
8.16M shares
derived: sum of 4 quarters · filed 2017-08-02
2017-03-312.30M shares
10-Q · filed 2017-05-01
8.51M shares
derived: sum of 4 quarters · filed 2017-05-01
2016-12-312.88M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
6.24M shares
10-K · filed 2017-02-27
2016-09-302.04M shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
4.83M shares
derived: sum of 4 quarters · filed 2016-11-03
2016-06-301.30M shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
2016-03-3121.50K shares
10-Q · filed 2016-05-04
2015-12-311.47M shares
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
2.34M shares
10-K · filed 2016-02-29
2014-12-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
19.09K shares
10-K · filed 2015-03-02
2014-09-300.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04
27.93K shares
derived: sum of 4 quarters · filed 2015-03-02
2014-06-300.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31
28.52K shares
derived: sum of 4 quarters · filed 2015-03-02
2014-03-3119.09K shares
10-Q · filed 2014-05-01
28.84K shares
derived: sum of 4 quarters · filed 2015-03-02
2013-12-318.84K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
13.31K shares
10-K · filed 2015-03-02
2013-09-30589.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30
10.74K shares
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30318.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
122.75K shares
derived: sum of 4 quarters · filed 2015-03-02
2013-03-313.57K shares
10-Q · filed 2013-05-07
163.51K shares
derived: sum of 4 quarters · filed 2015-03-02
2012-12-316.27K shares
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
181.98K shares
10-K · filed 2015-03-02
2012-09-30112.59K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07
2012-06-3041.09K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02
2012-03-3122.03K shares
10-Q · filed 2012-05-03
2011-12-312.16M shares
10-K · filed 2014-02-20
2010-12-31495.10K shares
10-K · filed 2013-02-21
2009-12-3159.76K shares
10-K · filed 2012-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78